Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,430 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Opiate Dependence
Interventions: employment-based reinforcement; Combination Product
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Postoperative Pain
Interventions: Q8003, Morphine sulfate, Oxycodone HCl, Oxycodone HCl 4mg; Drug
Lead sponsor: QRxPharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Phoenix, Arizona • Anaheim, California • Owings Mills, Maryland + 3 more

Conditions: Acute Pain
Interventions: Cebranopadol, Oxycodone IR, Placebo Only, Placebo; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Sheffield, Alabama • Little Rock, Arkansas • Tampa, Florida + 7 more

Conditions: Major Depressive Disorder, Treatment Resistant Depression, Depression
Interventions: AXS-05 (dextromethorphan and bupropion) oral tablets; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 51
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 46 more

Conditions: Opioid Dependence
Interventions: buprenorphine/naloxone; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 16 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: buprenorphine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions: Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Adult Solid Neoplasm
Interventions: Gamma-Secretase Inhibitor RO4929097, Ketoconazole, Rifampin, Midazolam Hydrochloride, Omeprazole, Tolbutamide, Dextromethorphan Hydrobromide, Pharmacological Study, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Blood Oxygen Level Dependent Imaging, Papaverine Hydrochloride, Stereotactic Body Radiation Therapy; Procedure · Drug · Radiation
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chronic Pain
Interventions: Hydrocodone Bitartrate; Drug
Lead sponsor: Zogenix, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 50
States / cities: Phoenix, Arizona • Sierra Vista, Arizona • Little Rock, Arkansas + 44 more

Conditions: Healthy
Interventions: morphine sulfate sustained-release capsules, KADIAN (morphine sulfate sustained-release) capsules; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Osteoarthritis
Interventions: Oxycodone, Placebo, PF-000592379; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 21
States / cities: Mobile, Alabama • Tucson, Arizona • Carmichael, California + 17 more

Conditions: Opioid Misuse and Addiction, Pain
Interventions: Oxycodone, Zero Opioid Protocol; Drug · Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bipolar Disorder, Alcohol Dependence
Interventions: Naltrexone hydrochloride, Placebo; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pain
Interventions: IV Acetaminophen (Treatment A), Oral Acetaminophen (Treatment B), Placebo (Treatment C), Morphine (Treatment D); Drug · Other
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cocaine-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1993
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Dependence, Substance-Related Disorders
Interventions: Buprenorphine/naloxone; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 582 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2001
U.S. locations: 5
States / cities: Los Angeles, California • Tampa, Florida • Hines, Illinois + 2 more

Conditions: Opiates, Healthy
Interventions: Vicks VapoInhaler, Poppy seeds; Drug · Other
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain, Postoperative, Postoperative Nausea and Vomiting, Postoperative Hemorrhage, Body Weight Changes
Interventions: Norco (Hydrocodone and Acetaminophen), Percocet (Oxycodone and Acetaminophen), Dilaudid (hydromorphone), Tylenol (Acetaminophen); Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Caesarean Delivery
Interventions: TAP Block, Ropivacaine, Acetaminophen, Morphine; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 3
States / cities: Boston, Massachusetts • Lebanon, New Hampshire

Conditions: Acute Pain
Interventions: 2 mg IV hydromorphone; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 298 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
Interventions: Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna; Drug
Lead sponsor: Edgar LeClaire, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Wichita, Kansas

Conditions: Healthy
Interventions: Placebo, Oxycodone 20mg, gabapentin 600 mg, Gabapentin 1200mg, Gabapentin 600 mg + Oxycodone 20 mg, Gabapentin 1200 mg + Oxycodone 20 mg; Drug
Lead sponsor: Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Chronic Pain
Interventions: Cold pressor test; Other
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Employment-Based Depot Naltrexone Clinical Trial

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

Open-Label Safety Study of AXS-05 in Subjects With Depression

Dane County Drug Court Study for Addicted Offenders

Buprenorphine Disposition and Cyclosporine

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce

A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

Toward Zero Prescribed Opioids for Outpatient General Surgery

Optimizing Pharmacotherapy for Bipolar Alcoholics

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

IV Cocaine Abuse: A Laboratory Model - 3

Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14

Factors Affecting Methamphetamine and Opiates Drug Testing

Post-tonsillectomy Pain Control in Adults

Comparison of Different Methods of Pain Control After Cesarean Section for Patients on Buprenorphine or Methadone

Safety of Hydromorphone in Adult Patients Presenting to the Emergency Department With Acute Severe Pain

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users

The Effects of Water Temperature on the Cold Pressor Test